Functional analysis of clinical BARD1 germline variants
Open Access
- 1 August 2019
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 5 (4)
Abstract
Germline pathogenic variants in BRCA1/2 account for one-third of familial breast cancers. The majority of BRCA1 function requires heterodimerization with BARD1. In contrast to BRCA1, BARD1 is a low-penetrance gene with an unclear clinical relevance, partly because of limited functional evidence. Using patient-derived lymphoblastoid cells, we functionally characterized two pathogenic variants (c.1833dupT, c.2099delG) and three variants of uncertain significance (VUSs) (c.73G>C, c.1217G>A, c.1918C>A). Three of these patients had breast cancers, whereas the remaining had colorectal cancers (n = 3). Both patients with pathogenic variants (c.1833dupT, c.2099delG) developed breast cancers with aggressive disease phenotypes such as triple-negative breast cancer and high cancer grades. As BARD1 encompasses multiple functional domains, including those of apoptosis and homologous recombination repair, we hypothesized that the function being impaired would correspond with the domain where the variant was located. Variants c.1918C>A, c.1833dupT, c.1217G>A, and c.2099delG, located within and proximal to apoptotic domains of ankyrin and BRCT, were associated with impaired apoptosis. Conversely, apoptosis function was preserved in c.73G>C, which was distant from the ankyrin domain. All variants displayed normal BRCA1 heterodimerization and RAD51 colocalization, consistent with their location being distal to BRCA1—and RAD51-binding domains. In view of deficient apoptosis, VUSs (c.1217G>A and c.1918C>A) may be pathogenic or likely pathogenic variants. In summary, functional analysis of BARD1 VUSs requires a combination of assays and, more importantly, the use of appropriate functional assays with consideration to the variant's location.Keywords
This publication has 35 references indexed in Scilit:
- Cancer predisposing BARD1 mutations in breast–ovarian cancer familiesBreast Cancer Research and Treatment, 2011
- BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancerGenes, Chromosomes and Cancer, 2010
- Cancer predisposing missense and protein truncatingBARD1mutations in non-BRCA1orBRCA2breast cancer familiesHuman Mutation, 2010
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage ResponseCurrent Biology, 2009
- Functional Assays for Classification ofBRCA2Variants of Uncertain SignificanceCancer Research, 2008
- Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignanciesJournal of Medical Genetics, 2006
- Is there more to BARD1 than BRCA1?Nature Reviews Cancer, 2006
- Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosisInternational Journal of Cancer, 2005
- Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancerJournal of Medical Genetics, 2005
- Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal InstabilityMolecular and Cellular Biology, 2003